0000899243-20-030020.txt : 20201030 0000899243-20-030020.hdr.sgml : 20201030 20201030195846 ACCESSION NUMBER: 0000899243-20-030020 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20201027 FILED AS OF DATE: 20201030 DATE AS OF CHANGE: 20201030 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yi Kathy CENTRAL INDEX KEY: 0001697802 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39311 FILM NUMBER: 201278696 MAIL ADDRESS: STREET 1: 501 CANAL BLVD. STREET 2: POINT RICHMOND TECH CENTER CITY: RICHMOND STATE: CA ZIP: 94804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001805387 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 DARTMOUTH STREET STREET 2: SUITE 502 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 844-304-2048 MAIL ADDRESS: STREET 1: 131 DARTMOUTH STREET STREET 2: SUITE 502 CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II DATE OF NAME CHANGE: 20200303 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-10-27 0 0001805387 Cerevel Therapeutics Holdings, Inc. CERE 0001697802 Yi Kathy C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 131 DARTMOUTH STREET, SUITE 502 BOSTON MA 02116 0 1 0 0 Chief Financial Officer Stock Option (Right to Buy) 3.50 2029-06-25 Common Stock 426582 D Stock Option (Right to Buy) 10.28 2029-06-25 Common Stock 142194 D 25% of the shares subject to this option vested and became exercisable on June 10, 2020, with remainder vesting in 36 equal monthly installments thereafter. Exhibit 24 - Power of Attorney /s/ Bryan K. Phillips, as Attorney-in-Fact 2020-10-30 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                   POWER OF ATTORNEY

        The undersigned hereby constitutes and appoints each of Bryan K.
Phillips and Mark Bodenrader, signing singly, and with full power of
substitution, the undersigned's true and lawful attorney-in-fact to:

        (1) execute for and on behalf of the undersigned, in the undersigned's
capacity as officer and/or director of Cerevel Therapeutics Holdings, Inc., a
Delaware corporation (the "Company"), from time to time the following U.S.
Securities and Exchange Commission (the "SEC") forms: (i) Form ID, including any
attached documents (such as Update Passphrase Authentication), to effect the
assignment of codes to the undersigned to be used in the transmission of
information to the SEC using the EDGAR System; (ii) Form 3, Initial Statement of
Beneficial Ownership of Securities, including any attached documents; (iii) Form
4, Statement of Changes in Beneficial Ownership of Securities, including any
attached documents; (iv) Form 5, Annual Statement of Beneficial Ownership of
Securities in accordance with Section 16(a) of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), and the rules thereunder, including any
attached documents; and (v) amendments of each thereof, in accordance with the
Exchange Act, and the rules thereunder, including any attached documents;

        (2) do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form 3, 4
or 5 or any amendment(s) thereto and timely file such form(s) with the SEC and
any securities exchange, national association or similar authority; and

        (3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

        The undersigned hereby grants to each such attorney-in-fact, acting
singly, full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
The undersigned hereby agrees to indemnify the attorneys-in-fact and the Company
from and against any demand, damage, loss, cost or expense arising from any
false or misleading information provided by the undersigned to the attorneys-in-
fact.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.  This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company.  This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in- fact ceases to be an employee
of the Company.

                                [Signature Page Follows]

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of October 30, 2020.

                                        /s/ Kathy Yi
                                        ---------------------------
                                        Signature

                                        Kathy Yi
                                        ------------------------
                                        Print Name